ESTIMATED
04/26/2024
04/26/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.38 | -$0.38 | -$0.38 |
Q2 2024 | 4 | -$0.49 | -$0.32 | -$0.41 |
Q3 2024 | 1 | -$0.43 | -$0.43 | -$0.43 |
Q4 2024 | 1 | -$0.41 | -$0.41 | -$0.41 |
Q1 2025 | 2 | -$0.36 | -$0.36 | -$0.36 |
Q2 2025 | 2 | $0.06 | $0.06 | $0.06 |
Q3 2025 | 2 | -$0.10 | -$0.10 | -$0.10 |
Q4 2025 | 2 | $0.01 | $0.01 | $0.01 |
Actinium Pharmaceuticals, Inc. last posted its earnings results on Friday, April 26th, 2024. The company reported $-0.31 earnings per share for the quarter, topping analysts' consensus estimates of $-0.42 by $0.11. The company had revenue of 0 for the quarter and had revenue of 81,000 for the year. Actinium Pharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-1.83 diluted earnings per share) and currently has a price-to-earnings ratio of -4.18. Actinium Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 04/26/2024 | Q1 2024 | -$0.42 | -$0.31 | 0.11 | $11.67 M | $0 | 03/29/2024 | Q4 2023 | -$0.54 | -$0.34 | 0.2 | $81,000 | $81,000 | 11/02/2023 | Q3 2023 | -$0.53 | -$0.49 | 0.04 | $0 | 08/14/2023 | Q2 2023 | -$0.50 | -$0.58 | -0.08 | $0 | 05/15/2023 | Q1 2023 | -$0.42 | -$0.41 | 0.01 | $0 | 03/31/2023 | Q4 2022 | -$0.39 | $114,000 | 11/14/2022 | Q3 2022 | -$0.30 | -$0.37 | -0.07 | $45,000 | 08/12/2022 | Q2 2022 | -$0.23 | -$0.33 | -0.1 | $45,000 | 05/13/2022 | Q1 2022 | -$0.31 | -$0.23 | 0.08 | $940,000 | 03/25/2022 | Q4 2021 | -$0.30 | -$0.37 | -0.07 | $106,667 | $23,000 | 11/12/2021 | Q3 2021 | -$0.29 | -$0.30 | -0.01 | $70,000 | $233,000 | 07/30/2021 | Q2 2021 | -$0.30 | -$0.25 | 0.05 | $133,000 | $266,000 | 05/14/2021 | Q1 2021 | -$0.29 | -$0.29 | 0 | $622,000 | 03/31/2021 | Q4 2020 | -$0.37 | -$0.35 | 0.02 | $0 | 10/23/2020 | Q3 2020 | -$0.44 | -$0.36 | 0.08 | $0 | 08/14/2020 | Q2 2020 | -$0.40 | -$0.41 | -0.01 | $0 | 06/29/2020 | Q1 2020 | -$0.98 | $0 | 05/08/2020 | Q4 2019 | -$0.80 | $0 | 11/12/2019 | Q3 2019 | -$1.20 | -$1.21 | -0.01 | $0 | 08/09/2019 | Q2 2019 | -$1.20 | -$0.99 | 0.21 | $0 |
---|
A. Actinium Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off last year's report dates.
A. In the previous quarter, Actinium Pharmaceuticals, Inc. (AMEX:ATNM) reported $-0.31 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.42 by $0.11.
A. The conference call for Actinium Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Actinium Pharmaceuticals, Inc.'s latest earnings report can be read online.
A. Actinium Pharmaceuticals, Inc. (AMEX:ATNM) has a recorded annual revenue of $81,000.
A. Actinium Pharmaceuticals, Inc. (AMEX:ATNM) has a recorded net income of $81,000. Actinium Pharmaceuticals, Inc. has generated $-1.83 earnings per share over the last four quarters.
A. Actinium Pharmaceuticals, Inc. (AMEX:ATNM) has a price-to-earnings ratio of -4.18 and price/earnings-to-growth ratio is 0.11.